eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2004
vol. 8
 
Share:
Share:
abstract:

Effect of cyclophosphamide on tumorogenesis of the IL-6 and Hyper-IL-6 gene modified murine melanoma cells

Andrzej Mackiewicz
,
Dariusz Iżycki
,
Katarzyna Baksalary-Iżycka
,
Katarzyna Gryska
,
Maria Łaciak
,
Sergiusz Nawrocki

Współcz Onkol (2004) vol. 8: 3 (124-131)
Online publish date: 2004/04/22
View full text Get citation
 
Background: The study was aimed at evaluating the effect of cyclophosphamide on the melanogenesis of the IL-6 and hyper-IL-6 gene modified murine melanoma cells.
Animals and Experimental Design: Sixty-three (n=63), six-week-old C57/Bl6xC3H chimeric mice were injected with ”wild” type or with interleukin-6 (IL-6) or Hyper-6 (H6) gene modified B-78 murine melanoma cells and/or cyclophosphamide. Control groups were injected s.c. with ”wild” type (group I; n=7), IL-6 (group II; n=7), or H-6 (group III; n=7) gene modified B-78 murine melanoma cells (5x105 cells). In the experimental groups IA, IIA, and IIIA animals were intraperitoneally (i.p.) injected with cyclophosphamide (100 mg/kg) two days before inoculation of B-78 (group IA; n=7), B-78/IL-6 (group IIA; n=7) and
B-78/H6 (group IIIA; n=7) melanoma cells (s.c.; 5x105 cells). In the experimental groups IB (n=7), IIB (n=7) and IIIB (n=7) combined treatment of B-78, B-78/IL-6
and B-78/H6 (respectively; s.c.;
5x105 cells) and cyclophosphamide
(500 mg/kg; i.p., two days before inoculation of B-78 cells) was applied. We evaluated the kinetics of the tumor growth, mean survival time of the animals and immune response. The non-specific (NK cells) immunotoxicity as well as Th1/Th2 and Tc1/Tc2 shift were analyzed by flow cytometry.
Results: The kinetics of the tumor growth study revealed significantly important inhibition of tumor growth in group III mice (day 35, <20 cm3) treated with B-78/H6 mono-therapy. Application of combined B-78/IL-6 and B-78/H6 with cyclophosphamide (100 mg/kg; group IIIA) treatment resulted in significant extension of the survival and tumor growth inhibition.
Flow cytometric analysis of the non-specific cytotoxicity showed no significant difference between control and experimental groups as well as in the Th1/Th2 and Tc1/Tc2 ratios.
Conclusions: Application of low doses of cyclophosphamide resulted in inhibition of the potency of tumor to grow in vivo.
keywords:

cyclophosphamide, gene therapy, melanoma malignum

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.